Different bleeding risk in type 2A and 2M von Willebrand disease: A 2-year prospective study in 107 patients

Journal of Thrombosis and Haemostasis

Volumn 10, Issue 4, 2012, Pages 632-638

  Castaman, G ^a   Federici, A B ^b   Tosetto, A ^a   La Marca, S ^c   Stufano, F ^c   Mannucci, P M ^d   Rodeghiero, F ^a  

^a SAN BORTOLO HOSPITAL   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c IRCCS A Bianchi Bonomi Hemophilia and Thrombosis Center   (Italy)

^d FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Gene mutation; Inherited bleeding disorder; Von Willebrand disease; Von Willebrand factor

Indexed keywords

BLOOD CLOTTING FACTOR 8; VON WILLEBRAND FACTOR;

ADOLESCENT; ADULT; AGED; ANAMNESIS; ARTICLE; BLEEDING; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GENE MUTATION; HUMAN; INCIDENCE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; VON WILLEBRAND DISEASE; VON WILLEBRAND DISEASE TYPE 2M;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FACTOR VIII; FEMALE; GASTROINTESTINAL HEMORRHAGE; GENETIC PREDISPOSITION TO DISEASE; HEMORRHAGE; HEMOSTATIC TECHNIQUES; HUMANS; INCIDENCE; ITALY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; PHENOTYPE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; VON WILLEBRAND DISEASE, TYPE 2; VON WILLEBRAND FACTOR; YOUNG ADULT;

EID: 84859169124     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2012.04661.x     Document Type: Article

References (42)

1. Castaman G, Tosetto A, Rodeghiero F. von Willebrand disease. In: Key N, O'Shaughnessy D, Makris M, Lillicrap D, eds. Practical Hemostasis and Thrombosis, 2nd edn. Oxford: Blackwell, 2009: 73-87.
2. Sadler JE, Budde U, Eikenboom JC, Favaloro EJ, Hill FG, Holmberg L, Ingerslev J, Lee CA, Lillicrap D, Mannucci PM, Mazurier C, Meyer D, Nichols WL, Nishino M, Peake IR, Rodeghiero F, Schneppenheim R, Ruggeri ZM, Srivastava A, Montgomery RR et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006; 4: 2103-14.
3. Goodeve A. The genetic basis of von Willebrand disease. Blood Rev 2010; 24: 123-34.
4. Lyons SE, Bruck ME, Bowie EJW, Ginsburg D. Impaired cellular transport produced by a subset of type IIA von Willebrand disease mutations. J Biol Chem 1992; 267: 4424-30.
5. Zimmerman TS, Dent JA, Ruggeri ZM, Nannini LH. Subunit composition of plasma von Willebrand factor. Cleavage is present in normal individuals, increased in IIA and IIB von Willebrand disease, but minimal in variants with aberrant structure of individual oligomers (types IIC, IID, and IIE). J Clin Invest 1986; 77: 947-51.
6. James PD, Notley C, Hegadorn C, Leggo J, Tuttle A, Tinlin S, Brown C, Andrews C, Labelle A, Chirinian Y, O'Brien L, Othman M, Rivard G, Rapson D, Hough C, Lillicrap D. The mutational spectrum of type 1 von Willebrand disease: results from a Canadian cohort study. Blood 2007; 109: 145-54.
7. Goodeve A, Eikenboom J, Castaman G, Rodeghiero F, Federici AB, Batlle J, Meyer D, Mazurier C, Goudemand J, Schneppenheim R, Budde U, Ingerslev J, Habart D, Vorlova Z, Holmberg L, Lethagen S, Pasi J, Hill F, Hashemi Soteh M, Baronciani L. Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD). Blood 2007; 109: 112-21.
8. Cumming A, Grundy P, Keeney S, Lester W, Enayat S, Guilliatt A, Bowen D, Pasi J, Keeling D, Hill F, Bolton-Maggs PH, Hay C, Collins P. An investigation of the von Willebrand factor genotype in UK patients diagnosed to have type 1 von Willebrand disease. Thromb Haemost 2006; 96: 630-41.
9. James PD, Notley C, Hegadorn C, Poon M-C, Walker I, Rapson D, Lillicrap D, Association of Hemophilia Clinic Directors of Canada. Challenges in defining type 2M von Willebrand disease: results from a Canadian cohort study. J Thromb Haemost 2007; 5: 914-22.
10. Meyer D, Fressinaud E, Mazurier C. Clinical, laboratory, and molecular markers of type 2 von Willebrand disease. In: Federici AB, Lee CA, Berntorp EE, Lillicrap D, Montgomery RR, eds. Von Willebrand Disease. Basic and Clinical Aspects. Oxford: Wiley-Blackwell, 2011: 137-47.
11. Penas N, Perez-Rodriguez A, Torea JH, Loures E, Noya MS, Lopez-Fernandez MF, Batlle J. von Willebrand disease R1374C: type 2A or 2M? A challenge to the revised classification. High frequency in the northwest of Spain (Galicia). Am J Hematol 2005; 80: 188-96.
12. Casonato A, Pontara E, Sartorello F, Bertomoro A, Durante C, Girolami A. Type 2M von Willebrand disease variant characterized by abnormal von Willebrand factor multimerization. J Lab Clin Med 2001; 137: 70-6.
13. Nitu-Whalley IC, Riddell A, Lee CA, Pasi KJ, Owens D, Enayat MS, Perkins SJ, Jenkins PV. Identification of type 2 von Willebrand disease in previously diagnosed type 1 patients: a reappraisal using phenotypes, genotypes and molecular modelling. Thromb Haemost 2000; 84: 998-1004.
14. Batlle J, Pérez-Rodriguez A, Franqueira MD, Lopez-Fernandez MF. Type 2M von Willebrand disease: a variant of type 2A? J Thromb Haemost 2008; 6: 388-90.
15. Federici AB, Mannucci PM, Castaman G, Baronciani L, Bucciarelli P, Canciani MT, Pecci A, Lenting PJ, De Groot PG. Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients. Blood 2009; 113: 526-34.
16. Castaman G, Tosetto A, Federici AB, Rodeghiero F. Bleeding tendency and efficacy of anti-haemorrhagic treatments in patients with type 1 von Willebrand disease and increased von Willebrand factor clearance. Thromb Haemost 2011; 105: 647-54.
17. Tosetto A, Rodeghiero F, Castaman G, Goodeve A, Federici AB, Battle J, Meyer D, Fressinaud E, Mazurier C, Goudemand J, Eikenboom JC, Schneppenheim R, Budde U, Ingerslev J, Vorlova Z, Habart D, Holmberg L. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost 2006; 4: 766-73.
18. Castaman G, Lethagen S, Federici AB, Tosetto A, Goodeve A, Budde U, Batlle J, Meyer D, Mazurier C, Fressinaud E, Goudemand J, Eikenboom J, Schneppenheim R, Ingerslev J, Vorlova Z, Habart D, Holmberg L, Pasi J, Hill F, Peake I, et al. Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD. Blood 2008; 111: 3531-9.
19. Castaman G, Giacomelli SH, Jacobi P, Obser T, Budde U, Rodeghiero F, Haberichter SL, Schneppenheim R. Homozygous type 2N R854W von Willebrand factor is poorly secreted and causes a severe von Willebrand disease phenotype. J Thromb Haemost 2010; 8: 2011-6.
20. Hosmer DW, Lemeshow S. Applied Survival Analysis. New York, USA: John Wiley & Sons, 1999.
21. Rothman KJ, Greenland S, Lash TL. Modern Epidemiology, 3rd edn. Philadelphia, USA: Lippincott, Williams and Wilkins, 2008.
22. Budde U, Schneppenheim R, Eikenboom J, Goodeve A, Will K, Drewke E, Castaman G, Rodeghiero F, Federici AB, Batlle J, Pérez A, Meyer D, Mazurier C, Goudemand J, Ingerslev J, Habart D, Vorlova Z, Holmberg L, Lethagen S, Pasi J et al. Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD). J Thromb Haemost 2008; 6: 762-71.
23. Rodeghiero F, Castaman G, Tosetto A, Batlle J, Baudo F, Cappelletti A, Casana P, De Bosch N, Eikenboom JC, Federici AB, Lethagen S, Linari S, Srivastava A. The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study. J Thromb Haemost 2005; 3: 2619-26.
24. Mannucci PM. Treatment of von Willebrand's Disease. N Engl J Med 2004; 351: 683-94.
25. Sixma JJ, Sakariassen KS, Beeser-Visser NH, Ottenhof-Rovers M, Bolhuis PA. Adhesion of platelets to human artery subendothelium: effect of factor VIII-von Willebrand factor of various multimeric composition. Blood 1984; 63: 128-39.
26. Danesh BJZ, Spliadis C, Willaims CB, Zambartas CM. Angiodysplasia: an uncommon cause of chronic bleeding : colonoscopic evaluation of 1050 patients with rectal bleeding and anemia. Int J Colorectal Dis 1987; 2: 218-22.
27. Sharma R, Gorbien MJ. Angiodysplasia and lower gastrointestinal tract bleeding in elderly patients. Arch Intern Med 1995; 155: 807-12.
28. Fressinaud E, Meyer D. International survey of patients with von Willebrand disease and angiodysplasia. Thromb Haemost 1993; 70: 546.
29. Iannuzzi MC, Hidaka N, Boehnke M, Bruck ME, Hanna WT, Collins FS, Ginsburg D. Analysis of the relationship of von Willebrand disease and hereditary haemorrhagic telangiectasia and identification of a potential type IIA vWD mutation (Ile865 to Thr). Am J Hum Genet 1991; 48: 757-63.
30. Morris ES, Hampton KK, Nesbitt IM, Preston FE, Thomas EG, Makris M. The management of von Willebrand's disease-associated gastrointestinal angiodysplasia. Blood Coagul Fibrinolysis 2001; 12: 143-8.
31. Satoh Y, Kita H, Kihira K, Mutoh H, Osawa H, Satoh K, Ido K, Skata Y, Sugano K. Gastrointestinal angiodysplasia in a patient with type 2 von Willebrand's disease and analysis of exon 28 of the von Willebrand factor gene. Am J Gastroenterol 2004; 99: 2495-8.
32. Makris M. Gastrointestinal bleeding in von Willebrand disease. Thromb Res 2006; 1: 118.
33. Warkentin TE, Moore JC, Morgan DG. Aortic stenosis and bleeding gastrointestinal angiodysplasia: is acquired von Willebrand's disease the link? Lancet 1992; 340: 35-7.
34. Veyradier A, Balian A, Wolf M, Giraud V, Montembault S, Obert B, Dagher I, Chapu J-C, Meyer D, Naveau S. Abnormal von Willebrand factor in bleeding angiodysplasias of the digestive tract. Gastroenterology 2001; 120: 346-53.
35. Sadler JE. Aortic stenosis, von Willebrand factor, and bleeding. N Engl J Med 2003; 349: 343-9.
36. Vincentelli A, Susen S, Le Tourneau T, Six I, Fabre O, Juthier F, Bauters A, Decoene C, Goudemand J, Prat A, Jude B. Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med 2003; 349: 343-9.
37. Starke RD, Ferraro F, Paschalaki KE, Dryden NH, McKinnon TAJ, Sutton RE, Payne EM, Haskard DO, Hughes AD, Cutler DF, Laffan MA, Randi AM. Endothelial von Willebrand factor regulates angiogenesis. Blood 2011; 117: 1071-80.
38. Mannucci PM, Moia M, Rebulla P, Altieri D, Monteagudo J, Castillo R. Correction of the bleeding time in treated patients with severe von Willebrand disease is not solely dependent on the normal multimeric structure of plasma von Willebrand factor. Am J Hematol 1987; 25: 55-65.
39. Mannucci PM, Tenconi PM, Castaman G, Rodeghiero F. Comparison of four virus-inactivated plasma concentrates for treatment of severe von Willebrand disease: a cross-over randomized trial. Blood 1992; 79: 3130-7.
40. Mannucci PM, Pareti FI, Holmberg L, Nilsson IM, Ruggeri ZM. Studies on the prolonged bleeding time in von Willebrand's disease. J Lab Clin Med 1976; 88: 662-71.
41. Tosetto A, Castaman G, Rodeghiero F. Evidence-based diagnosis of type 1 von Willebrand disease: a Bayes theorem approach. Blood 2008; 111: 3998-4003.
42. Rodeghiero F, Castaman G, Tosetto A. How I treat von Willebrand disease. Blood 2009; 114: 1158-65.